{"entity":{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","aka":["Zelgen","泽璟制药"],"tldr":"Zelgen developed donafenib, the deuterated sorafenib that beat the original in first-line liver cancer and was approved in China in 2021.","summary":"Suzhou Zelgen Biopharmaceuticals, based in Suzhou, founded in 2009 and listed as 688266.SS, developed donafenib, the deuterated version of sorafenib that beat the original in first-line liver cancer and was approved in China in 2021. Donafenib, sold as Zepsun, was approved in 2021 for hepatocellular carcinoma and in 2022 for thyroid cancer on the strength of the ZGDH3 trial against sorafenib; the pipeline includes jaktinib, a JAK inhibitor for myelofibrosis, and recombinant human thrombin, and the company was among the first listed on Shanghai's STAR Market before reaching profitability. OnCo links it to donafenib and to ZGDH3. Whether a deuterated improvement on an older drug can hold its place as immunotherapy combinations take over first-line liver cancer is the open question. Donafenib has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.zelgen.com/en/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["donafenib","zg006"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["zgdh3","nct05978284","nct06283719","nct07038096","nct06558227","nct06903377","nct07258121","nct06440057","nct05584800","nct06938880","nct06883526","nct06927687"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.zelgen.com/en/","ticker":"688266.SS","founded":2009,"investors":[],"funding":[]},"route":"/companies/zelgen/","neighbours":{"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"donafenib","kind":"drug","name":"Donafenib","route":"/drugs/donafenib/"},{"id":"gecacitinib","kind":"drug","name":"Gecacitinib","route":"/drugs/gecacitinib/"},{"id":"zg006","kind":"drug","name":"ZG006","route":"/drugs/zg006/"}],"trial":[{"id":"nct04971473","kind":"trial","name":"Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal","route":"/trials/nct04971473/"},{"id":"nct06283719","kind":"trial","name":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in P","route":"/trials/nct06283719/"},{"id":"nct06440057","kind":"trial","name":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.","route":"/trials/nct06440057/"},{"id":"nct04964284","kind":"trial","name":"rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)","route":"/trials/nct04964284/"},{"id":"nct07189455","kind":"trial","name":"Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer","route":"/trials/nct07189455/"},{"id":"nct06558227","kind":"trial","name":"Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma","route":"/trials/nct06558227/"},{"id":"nct06903377","kind":"trial","name":"Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06903377/"},{"id":"nct07080216","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer","route":"/trials/nct07080216/"},{"id":"nct06883526","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma","route":"/trials/nct06883526/"},{"id":"nct06927687","kind":"trial","name":"Study of ZG005 in Patients With Advanced Solid Tumors","route":"/trials/nct06927687/"},{"id":"nct05978284","kind":"trial","name":"Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","route":"/trials/nct05978284/"},{"id":"nct06938880","kind":"trial","name":"Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors","route":"/trials/nct06938880/"},{"id":"nct05584800","kind":"trial","name":"Study of ZGGS18 in Patients With Advanced Solid Tumors","route":"/trials/nct05584800/"},{"id":"nct07258121","kind":"trial","name":"Study of ZGGS34 in Participants With Advanced Solid Tumors","route":"/trials/nct07258121/"},{"id":"nct07038096","kind":"trial","name":"ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","route":"/trials/nct07038096/"},{"id":"zgdh3","kind":"trial","name":"ZGDH3 (donafenib vs sorafenib)","route":"/trials/zgdh3/"}]}}